9001-80-3

Basic information

• Product Name: 6-PHOSPHOFRUCTOKINASE TYPE VII
• Synonyms: 6-PHOSPHOFRUCTOKINASE TYPE VII;ATP: D-FRUCTOSE 6-PHOSPHATE 1-PHOSPHOTRANSFERASE TYPE VII;EC 2.7.1.11;FRUCTOSE-6-PHOSPHATE KINASE TYPE VII;fructose-6-phosphate kinase type vii*from bacillu;Kinase (phosphorylating), phosphofructo-;FRUCTOSE-6-PHOSPHATE KINASE TYPE VII*FRO M BACILLUS;FRUCTOSE-6-PHOSPHATE KINASE PRESTAINED&
• CAS NO: 9001-80-3
• Molecular Weight: 0
• EINECS: 232-633-5
• Mol File: 9001-80-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /lyophilized powder
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-PHOSPHOFRUCTOKINASE TYPE VII(CAS DataBase Reference)
• NIST Chemistry Reference: 6-PHOSPHOFRUCTOKINASE TYPE VII(9001-80-3)
• EPA Substance Registry System: 6-PHOSPHOFRUCTOKINASE TYPE VII(9001-80-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 9001-80-3(Hazardous Substances Data)

Usage

Description

6-Phosphofructokinase Type VII, also known as Bacillus stearothermophilus phosphofructokinase (BsPFK), is a homotetramer enzyme that plays a crucial role in the regulation of glycolysis. It catalyzes the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate, an essential step in the glycolytic pathway. BsPFK is allosterically inhibited by phosphoenolpyruvate (PEP), which binds along one dimer-dimer interface, allowing for the control of glycolytic flux in response to cellular energy needs.

Uses

Used in Research Applications:
6-Phosphofructokinase Type VII is used as a research tool for studying the regulation of glycolysis and the role of allosteric inhibition in metabolic pathways. It helps researchers understand the molecular mechanisms underlying the control of glycolytic flux and the interplay between different metabolic pathways.
Used in Pharmaceutical Industry:
6-Phosphofructokinase Type VII is used as a target for the development of drugs aimed at modulating glycolytic metabolism in various diseases, such as cancer and muscle disorders. By targeting this enzyme, it may be possible to develop therapies that can alter the metabolic profile of diseased cells, potentially leading to improved treatment outcomes.
Used in Muscle Disorders Research:
6-Phosphofructokinase Type VII is used as a research tool to investigate the molecular mechanisms underlying muscle disorders, such as dystrophy. The interaction between BsPFK and neuronal nitric oxide synthase (nNOS) has been shown to cause a defect in glycolytic metabolism and increased fatigability in dystrophic muscle. Understanding this interaction can help researchers develop targeted therapies for muscle disorders.